Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05486546
Other study ID # AMPLIO
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 15, 2022
Est. completion date December 1, 2023

Study information

Verified date April 2023
Source Vance Thompson Vision
Contact Daniel Terveen, MD
Phone 605-645-7999
Email daniel.terveen@vancethompsonvision.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Comparing post-operative visual acuity and patient reported satisfaction between Contoura with Phorcides and WaveLight Wavefront Optimized.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date December 1, 2023
Est. primary completion date September 1, 2023
Accepts healthy volunteers No
Gender All
Age group 21 Years to 38 Years
Eligibility Inclusion Criteria: - Patients at least age 21 years of age undergoing LASIK eye surgery - Willing and able to comprehend informed consent and complete 1 month post-op visit - Potential postoperative BCDVA of 20/20 or better in each eye based on Investigator's medical opinion - Candidates for Contoura with Phorcides (Myopic, astigmatism <3.0D) - Both eyes targeted for plano - Pre-operative total corneal Pachymetry 490um or above - Stable refractive error <0.50D change in preceding year - Good general and ocular health - Pre-operative exam completed within three months of surgery - SCL discontinued 3 days prior to pre-op exam and the procedure - Pachymetry above 490 with residual greater than 270um - Candidates who, as determined by the investigator, can safely undergo LASIK Exclusion Criteria: - Patients under 21 years of age - Concomitant ocular condition which would limit the BCVA at the discretion of the surgeon - Patients with usual relative and absolute contraindications for LASIK surgery (Patients with severe dry eye, recurrent corneal erosion, uncontrolled Glaucoma, collagen vascular disorders, keratoconus or signs of keratoconus, uncontrolled Diabetes, Herpes) - Pachymetry below 490 - Autoimmune or immunodeficiency diseases - Pregnant or nursing women - Patients with signs of inability to understand consent for study and procedure planned - Patients with history of previous ocular surgery - Patients with strabismus or amblyopia - Patients that have a BCDVA of 20/25 or worse in either eye

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Contoura with Phorcides
Participants that undergo LASIK surgery using Contoura with Phorcides Analytic Engine
Device:
WaveLight Wavefront Optimized
Participants that undergo LASIK surgery using WaveLight Wavefront Optimized

Locations

Country Name City State
United States Vance Thompson Vison Bozeman Montana
United States Vance Thompson Vision Fargo North Dakota
United States Vance Thompson Vision Omaha Nebraska
United States Vance Thompson Vision Sioux Falls South Dakota

Sponsors (2)

Lead Sponsor Collaborator
Daniel Terveen Alcon Research

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Post-Op UDVA Percent of participants with monocular UDVA of 20/16 or better 3 months post-op
Secondary Post-OP BCVA Percent of participants with monocular and binocular BCVA of 20/16 or better 3 months post-op
Secondary Residual Refractive Error Residual astigmatism and residual SE 3 months post-op
Secondary Low Contrast Visual Acuity 25% low contrast visual acuity post-op 3 months post-op
Secondary Pre-op and post-op visual acuity Percent of participants with post-op UDVA equal to or better than their pre-op CDVA 3 months post-op
Secondary Corrected Distance Visual Acuity Compare percent of participants with post-operative and pre-operative CDVA 3 months post-op
See also
  Status Clinical Trial Phase
Recruiting NCT04923841 - Myopia Control Using Bright Light Therapy, Myopic Defocus and Atropine N/A
Active, not recruiting NCT04080128 - Examination of Myopia Progression and Soft Bifocal Contact Lens Myopia Control N/A
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Completed NCT04604405 - Effects of 650nm Low Energy Light on Human Retina and Choroid Microcirculation N/A
Recruiting NCT05594719 - The Effect of Sun-like Spectrum With Different Spectrum Composition on Retinal Blood Flow N/A
Completed NCT05594732 - The Effects of Different Outdoor Light Exposure Modes on Retinal Blood Flow N/A
Completed NCT04492397 - Comparing The Performance Of Two Different Daily Disposable Lenses (MIKI) N/A
Completed NCT04536571 - Vision Stability and Preference for Soft Toric vs. Soft Spherical Contact Lenses N/A
Completed NCT06046209 - Comparing a Monthly Replacement Lens Versus a Daily Disposable Lens N/A
Recruiting NCT06344572 - Pivotal Study of SAT-001 in Treatment of Pediatric Patient With Myopia Phase 3
Recruiting NCT05611294 - Contralateral Study of Topography Guided LASIK Versus Small Incision Lenticule Extraction N/A
Completed NCT05656885 - Clinical Evaluation of Two Frequent Replacement Soft Spherical Contact Lenses N/A
Active, not recruiting NCT05534022 - Clinical Evaluation of a Myopia Control Lens in Slowing Myopia Progression. N/A
Completed NCT03934788 - the Clinical Performance of the Oxysoft Daily Disposable Silicone Hydrogel Soft Contact Lens N/A
Completed NCT03701516 - Clinical Evaluation of Etafilcon A Contact Lenses Using a Novel Molding Process 2 N/A
Completed NCT05538754 - Post-Market Evaluation of the EVO ICL N/A
Completed NCT03139201 - Clinical Performance of the OxyAqua Daily Disposable Silicone Hydrogel Soft Contact Lens N/A
Completed NCT02555722 - Evaluation of the CooperVision, Inc. Fanfilcon A and Enfilcon A Daily Wear Contact Lenses When Used for Frequent Replacement for up to One (1) Month of Daily Wear N/A
Not yet recruiting NCT06009458 - Acuity 200™ (Fluoroxyfocon A) Orthokeratology Contact Lens for Overnight Wear N/A
Recruiting NCT05548478 - Corneal Endothelial Cell Injury Induced by Mitomycin-C N/A